



**Universiteit  
Leiden**  
The Netherlands

**The presence of hemoglobin in cervicovaginal lavage is not associated with genital schistosomiasis in Zambian women from the BILHIV study**

Sturt, A.S.; Webb, E.L.; Phiri, C.R.; Mapani, J.; Mudenda, M.; Himschoot, L.; ... ; Bustinduy, A.L.

**Citation**

Sturt, A. S., Webb, E. L., Phiri, C. R., Mapani, J., Mudenda, M., Himschoot, L., ... Bustinduy, A. L. (2022). The presence of hemoglobin in cervicovaginal lavage is not associated with genital schistosomiasis in Zambian women from the BILHIV study. *Open Forum Infectious Diseases*, 9(12). doi:10.1093/ofid/ofac586

Version: Publisher's Version  
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)  
Downloaded from: <https://hdl.handle.net/1887/3766941>

**Note:** To cite this publication please use the final published version (if applicable).

# The Presence of Hemoglobin in Cervicovaginal Lavage Is Not Associated With Genital Schistosomiasis in Zambian Women From the BILHIV Study

Amy S. Sturt,<sup>1,✉</sup> Emily L. Webb,<sup>2,✉</sup> Comfort R. Phiri,<sup>3</sup> Joyce Mapani,<sup>4</sup> Maina Mudenda,<sup>4</sup> Lisa Himschoot,<sup>5</sup> Eyrun F. Kjetland,<sup>6,7</sup> Tobias Mweene,<sup>3</sup> Bruno Levecke,<sup>8</sup> Govert J. van Dam,<sup>9</sup> Paul L. A. M. Corstjens,<sup>10</sup> Helen Ayles,<sup>3,11</sup> Richard J. Hayes,<sup>2</sup> Suzanna C. Francis,<sup>2</sup> Lisette van Lieshout,<sup>9</sup> Piet Cools,<sup>5,8</sup> Isaiah Hansingo,<sup>4</sup> and Amaya L. Bustinduy<sup>11</sup>

<sup>1</sup>Department of Infectious Diseases, Veterans Affairs Health Care System, Palo Alto, California, USA, <sup>2</sup>MRC International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom, <sup>3</sup>Zambart, Lusaka, Zambia, <sup>4</sup>Department of Obstetrics and Gynecology, Livingstone Central Hospital, Livingstone, Zambia, <sup>5</sup>Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium, <sup>6</sup>Department of Infectious Diseases and Global Health, Norwegian Centre for Imported and Tropical Diseases, Oslo University Hospital, Oslo, Norway, <sup>7</sup>Discipline of Public Health Medicine, College of Health Sciences, University of Kwa-Zulu Natal, Durban, South Africa, <sup>8</sup>Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium, <sup>9</sup>Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands, <sup>10</sup>Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands, and <sup>11</sup>Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom

**Background.** Female genital schistosomiasis (FGS) occurs when *Schistosoma haematobium* eggs are deposited in reproductive tissue. Female genital schistosomiasis in the cervical mucosa is associated with increased vascularity. If FGS is associated with the presence of hemoglobin in cervicovaginal lavage (CVL), the use of urinary reagent strips to detect hemoglobin in CVL could supplement FGS diagnosis.

**Methods.** Nonmenstruating, nonpregnant, sexually active women aged 18–31 participating in the HPTN 071 (PopART) Population-Cohort were invited in 2 Zambian communities. Genital self-swabs and a urine specimen were collected at a home visit, and CVL and hand-held colposcopy were performed at a midwife led clinic visit. Urinary reagent strips were used to identify hemoglobin in CVL. Eggs and circulating anodic antigen (CAA) were detected from urine. Visual-FGS was defined as the presence of sandy patches, rubbery papules, or abnormal blood vessels. Polymerase chain reaction (PCR)-FGS was defined as *Schistosoma* deoxyribonucleic acid detected by real-time PCR on CVL or cervical or vaginal swab.

**Results.** Of 209 women with home genital swabs and companion CVL specimens, 66% (138 of 209) had detectable CVL hemoglobin, 13.4% (28 of 209) had PCR-defined FGS, and 17.2% (36 of 209) had visual-FGS. Active *Schistosoma* infection, diagnosed by CAA or urine microscopy, was present in 21.0% (44 of 209) participants. Active *Schistosoma* infection ( $P = .4$ ), PCR-FGS ( $P = 0.7$ ), and visual-FGS ( $P = 0.3$ ) were not associated with CVL hemoglobin presence. Results did not differ in subgroups with high infection burden (cycle threshold < 35 or 2–3 positive genital PCR).

**Conclusions.** Polymerase chain reaction-FGS, visual-FGS, and active *Schistosoma* infection were not associated with the presence of CVL hemoglobin. Further research is needed to establish accessible community-based FGS diagnostics.

**Keywords.** cervicovaginal lavage; female genital schistosomiasis; hematuria; hemoglobin; *Schistosoma haematobium*.

It is estimated that over 80 million African women are living with *Schistosoma haematobium* infection [1]. Female genital schistosomiasis (FGS) is caused when *S haematobium* eggs destined for excretion in the urinary bladder are deposited in reproductive tissue [2]. Female genital schistosomiasis of the

uterine cervix has been associated with characteristic clinical manifestations, such as sandy patches (homogenous and grainy), rubbery papules, and abnormal blood vessels [3]. The presence of parasite eggs in reproductive tissues may be associated with inflammation, fibrosis, and infertility [4, 5]. Parasite egg deposition in reproductive tissue may also lead to mucosal friability and vascularization. For example, the presence of *S haematobium* eggs in the pap smears of Zimbabwean women has been associated with contact bleeding [3]. In addition, the presence of *S haematobium* in the cervixes of Malawian women has been associated with a higher density of blood vessels than in the cervixes of Norwegian controls [6].

Establishing a diagnosis of FGS is challenging due to the lack of an appropriate reference standard, and currently both molecular and visual techniques are used. Molecular methods that detect *S haematobium* deoxyribonucleic acid (DNA), such as polymerase chain reaction (PCR) and recombinase

Received 20 July 2022; editorial decision 27 October 2022; accepted 02 November 2022  
Presented in part: American Society for Tropical Medicine and Hygiene annual meeting, Seattle, Washington, USA, October 31, 2022, Poster #518.

Correspondence: A. Sturt, MD, PhD, Department of Medicine, Veterans Affairs Health Care System, Building 101, Room B-134, 3801 Miranda Avenue, Palo Alto, CA 94306 (amysturt@stanford.edu).

Open Forum Infectious Diseases®

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

<https://doi.org/10.1093/ofid/ofac586>

polymerase assay, are not yet widely available in resource-limited settings [7, 8]. Although molecular methods have imperfect sensitivity, they show promise as highly specific FGS diagnostics [7, 9]. Although visual diagnosis, using portable colposcopy, is scalable and potentially more accessible than molecular methods, it suffers from a lack of specificity. Characteristic cervicovaginal sandy patches identified on portable colposcopy can also be associated with sexually transmitted infections (STIs), and abnormal blood vessels have been associated with cervical intraepithelial neoplasia 1–3 [3]. Urine microscopy and urine circulating anodic antigen (CAA) are useful diagnostic tools for diagnosing active *Schistosoma* infection, but they cannot confirm genital involvement. Urinary reagent strips are affordable, user-friendly, rapid, equipment free, and widely available diagnostics used in estimating the community prevalence of urinary schistosomiasis: hematuria is often used as a surrogate marker of *S haematobium* infection [10–12]. If FGS is associated with the presence of hemoglobin in cervicovaginal lavage (CVL) fluid, the use of urinary reagent strips to detect hemoglobin in CVL could supplement existing FGS diagnostic methods. However, the association of *Schistosoma* infection and FGS with CVL hemoglobin has not previously been described. The overall aim of this study is to evaluate whether the presence or absence of hemoglobin in CVL is associated with FGS and *Schistosoma* infection status.

## METHODS

### Study Setting and Participants

The cross-sectional bilharzia and HIV (BILHIV) study [9] was nested in HPTN 071 (PopART), a cluster-randomized trial to measure the impact of an HIV-1 combination prevention package [13]. As previously described, between January and August 2018, after the 36-month HPTN 071 (PopART) visit, community workers made home visits to women expressing interest in the BILHIV study [9]. Eligible women were 18–31 years old, not pregnant, sexually active, and resident in 1 of 2 urban communities that participated in HPTN 071 (PopART) in Livingstone, Zambia.

### Home- and Clinic-Based Sample and Image Collection

The home visit included written informed consent, a questionnaire, genital self-sampling (cervical and vaginal), and urine specimen collection, as previously described [9]. Questionnaires were administered by a field worker. Self-collected vaginal and cervical swab specimens were used for *Schistosoma* quantitative polymerase chain reaction (qPCR), and self-collected cervical swabs were used for characterization of STI by qPCR (Table 1). Urine specimens were used for detection of CAA and *S haematobium* eggs by microscopy (Table 1). Enrolled women who were not currently menstruating were then invited to attend Livingstone Central

**Table 1. Specimens Collected and Procedures Performed in the BILHIV Study**

Specimen or Procedure	Diagnostic Test	Home Visit	Clinic Visit
Urine	...	X	...
	Circulating Anodic Antigen	...	...
	Urine microscopy	...	...
Urine reagent strip	...	...	...
	...	...	...
Vaginal Swab	...	X	...
	<i>Schistosoma</i> PCR	...	...
Cervical Swab	...	...	...
	<i>Schistosoma</i> PCR	...	...
	STI diagnostics	...	...
Cervicovaginal Lavage	...	...	X
	<i>Schistosoma</i> PCR	...	...
	Urine reagent strip	...	...
Portable Colposcopy	...	...	X
	Cervicovaginal image capture	...	...

Abbreviations: BILHIV, bilharzia and HIV study; PCR, polymerase chain reaction.

Hospital cervical cancer clinic, where midwives collected CVL. After speculum insertion, a bulb syringe was used to flush normal saline (10 mL) across the cervix and vaginal walls for 1 minute. Cervicovaginal lavage fluid was collected from the posterior fornices.

At the clinic, cervicovaginal images were captured with a portable colposcope (MobileODT, Tel Aviv, Israel) and were evaluated by an expert reviewer (E.F.K.) for any of the 4 recognized FGS cervicovaginal manifestations: grainy sandy patches, homogenous yellow sandy patches, rubbery papules, and abnormal blood vessels [14]. Women with at least 1 of the visual manifestations of FGS [3, 14] or with any positive urine or genital *Schistosoma* diagnostic were treated free-of-charge with 40 mg/kg praziquantel. In line with national and local clinic protocols adapted to real-world resource limitations, human papillomavirus (HPV) testing was not performed. Cervical self-sampling for STIs was performed at the home visit and STI diagnostics were not done at the point-of-care. As per local guidelines, participants with suspected STIs were offered syndromic management [15].

Separate from BILHIV study procedures, participants could choose to engage in free cervical cancer screening using the visual inspection with acetic acid (VIA) technique. In the subset of women who engaged in screening, midwives applied 3%–5% acetic acid to the cervix after CVL collection, as previously described [16]. An opaque white reaction was classified as positive and no change was negative [17].

### Cervicovaginal Lavage Fluid Processing

Cervicovaginal lavage fluid was stored at  $-80^{\circ}\text{C}$  for a maximum of 20 months (range, 12–20), as previously described [18, 19].

Previously thawed CVL specimens were centrifuged at 320 ×g for 10 minutes and the supernatant was removed. A 10-μL aliquot of CVL supernatant was placed on a Multistix test strip (Siemens, Munich, Germany). As per the manufacturer's instructions, CVL hemoglobin concentrations were recorded after comparing the test strip with color categories representing approximate quantities of erythrocytes (ery) per microliter: none, trace, small (25 ery/μL); moderate (80 ery/μL); large (200 ery/μL) [18]. Cervicovaginal lavage fluid was considered positive for hemoglobin when any hemoglobin (at a level of trace or above) was detected in CVL fluid.

#### Urine Microscopy, Reagent Strip Testing, and Circulating Anodic Antigen

Up to 50 mL fresh urine was centrifuged and examined by microscopy for *S haematobium* eggs. The participant was considered to have urinary schistosomiasis if a pellet contained at least 1 *S haematobium* egg [9]. Hematuria was detected using Multistix test strip according to the manufacturer's instructions and was defined as the detection of any hemoglobin (at a level of trace or above) in urine. A lateral flow assay utilizing up-converting reporter particles for the quantification of CAA was performed on urine samples, as previously described [9, 20]. Analyzing the equivalent of 417-μL urine (wet reagent, UCAAhT417), a test result indicating a CAA value >0.6 pg/mL was considered positive [21].

#### Quantitative Polymerase Chain Reaction for Detection of *Schistosoma* Deoxyribonucleic Acid

Detection of the *Schistosoma*-specific internal-transcribed-spacer-2 (ITS-2) target by qPCR was performed at Leiden University Medical Center, as previously described [9, 22]. Deoxyribonucleic acid extraction of 200 μL CVL, cervical, or vaginal swab fluid was done with QIAamp spin columns (QIAGEN Benelux, Venlo, The Netherlands) according to manufacturer's guidelines. The qPCR output was reported in cycle threshold (Ct) values, and parasite DNA loads were categorized by the following prespecified values: high (Ct < 30), moderate (30 ≤ Ct < 35), low (35 ≤ Ct < 50), and negative (no amplification) [23].

#### Other Clinical Characteristics

Laboratory-based, fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab Combo Assay) was performed for HPTN 071 (PopART) Population Cohort participants at each study visit [13].

Sexually transmitted infections were quantified by qPCR using the S-DiaCTNG (for *Chlamydia trachomatis* and *Neisseria gonorrhoea*) and S-DiaMGTV kits (for *Mycoplasma genitalium* and *Trichomonas vaginalis*) (Diagenode Diagnostics, Seraing, Belgium) on DNA from cervical swabs at Ghent University (Ghent, Belgium) according to the manufacturer's instructions.

#### Female Genital Schistosomiasis and Schistosomiasis Definitions

In this study, we used various diagnostic tests to evaluate urinary *Schistosoma* infection (CAA and urine microscopy) and FGS (portable colposcopy, and *Schistosoma* DNA on CVL and genital swabs) as previously described [19, 24, 25]. As well as analyzing each diagnostic method separately for association with the outcome of this analysis (presence of CVL hemoglobin), we also used case definitions to characterize participants. Thus, participants were also grouped by diagnostic test results into 3 mutually exclusive categories: (1) FGS, at least 1 positive *Schistosoma* qPCR on a genital specimen (cervical swab, vaginal swab, and/or CVL); (2) "negative" FGS, negative results on all diagnostic methods; (3) "probable" FGS, negative genital *Schistosoma* qPCR but urinary schistosomiasis positive (as defined above), in combination with at least 1 of 4 clinical findings suggestive of FGS on any colposcope-obtained photograph [14]. Active *Schistosoma* infection was defined as detection of either CAA or *S haematobium* eggs in urine.

#### Statistical Methods

As previously described, all participants with FGS ( $n = 28$ ) and all participants with probable FGS ( $n = 24$ ) were selected for hemoglobin testing in CVL. Three FGS negative participants were selected for every FGS and probable FGS participant using a random number generator. The FGS negative participants were frequency matched by 7 age bands (18–19, 20–21, 22–23, 24–25, 26–27, 28–29, 30–31) to participants with FGS, resulting in a 3:1 ratio of FGS negative to FGS and probable FGS.

Participant characteristics were summarized by median and interquartile range for continuous variables and by frequency and percentage for categorical variables. Differences in baseline characteristics by CVL hemoglobin status were evaluated using Fisher's exact,  $\chi^2$ , or Kruskal-Wallis tests.

The primary analysis evaluated the association of FGS (PCR-defined or visually defined) and urinary schistosomiasis with the presence versus absence of CVL hemoglobin. Logistic regression was used to calculate crude and adjusted odds ratio for presence versus absence of CVL hemoglobin with the relevant FGS or *Schistosoma* infection definition. We adjusted for age, education, and community of residence and did not adjust for STIs because this variable is not consistently associated with FGS [24]. Data were analyzed using STATA 15.1 (Stata Corporation, College Station, TX).

#### Patient Consent Statement

The study was approved by the University of Zambia Biomedical Research Ethics Committee (011-08-17), the Zambia National Health Research Authority, and the London School of Hygiene and Tropical Medicine Ethics Committee (14506). Permission to conduct the study was given by Livingstone District Health Office and the Livingstone

Central Hospital superintendent. Participants provided written informed consent.

## RESULTS

The BILHIV study enrolled 603 eligible women, 209 (34.6%) of whom were included in the current analysis (Figure 1). Polymerase chain reaction-FGS was diagnosed in 13.4% (28 of 209) of participants, defined by a positive genital *Schistosoma* qPCR from any of the following sites: 8.6% (18 of 209) cervical swab, 6.7% (14 of 209) vaginal swab, and 6.7% (14 of 209) CVL. Visual-FGS was detected in 17.3% (36 of 208) of participants by expert review of digital images from hand-held colposcopy with 11.5% (24 of 209) having probable FGS. Of the participants who were negative on all diagnostic tests, 59.9% (157 of 262) were randomly selected for inclusion in this study. Of participants with PCR-FGS, 53.3% (15 of 28) had *Schistosoma* qPCR detected from more than 1 specimen (whether swab [cervical or vaginal] or cervicovaginal lavage, and 53.3% (15 of 28) had moderate/high genital *Schistosoma* DNA loads, as defined by cycle threshold <35. These subgroups with high-burden PCR-FGS overlapped by 11 participants.

The majority of patients (66.0%, 138 of 209) had detectable hemoglobin in their CVL fluid (trace, 15.3% [32 of 209]; small, 19.1% [40 of 209]; moderate, 15.3% [32 of 209]; large, 16.3% [34 of 209]). Compared to participants without hemoglobin detected in CVL, there was no difference in baseline characteristics such as age, marital status, education, or district of residence in participants with hemoglobin present in CVL (Table 2). There was strong evidence that a higher proportion of women with STIs had hemoglobin detected in CVL compared with women without STIs ( $P=0.04$ ). However, other reproductive health characteristics, such as lifetime number of sexual partners, HIV-1 status, VIA status, and contraceptive use, did not differ by CVL hemoglobin status. One third (34.9%) of participants had at least 1 STI (Table 2). At the conclusion of HPTN 071 (PopART), HIV-1 prevalence in this study population was 17.2% (36 of 209).

*Schistosoma haematobium* eggs were detected in urine microscopy in 12.0% (25 of 209) and CAA was detectable in 20.1% (42 of 209), and 21.1% (44 of 209) of participants had either positive urine microscopy or detectable CAA. Hematuria, detected by urine reagent strip, was present in 34.5% (72 of 209) of participants. There was no association between hematuria and the presence of hemoglobin in CVL ( $P=.9$ ). All participants with eggs detected on urine microscopy (12.0%, 25 of 209) had hematuria ( $P<.001$ ), whereas 76.2% (32 of 42) of participants with a detectable CAA had hematuria by urine reagent strip ( $P<.001$ ).


The crude and adjusted association of presence and absence of CVL hemoglobin was evaluated by FGS status (Table 3).

There was no evidence that either PCR-based or visually based methods (eg, portable colposcopy) of FGS detection were associated with the presence of CVL hemoglobin. There was no evidence that site and method of PCR-based FGS detection (whether cervical or vaginal, swab, or CVL) was associated with the presence of CVL hemoglobin (Figure 2). In addition, predefined FGS categories (definite or probable FGS) were not associated with the presence of CVL hemoglobin. A higher burden of FGS, whether defined by 2–3 positive genital PCR specimens, or lower PCR cycle threshold ( $Ct < 35$ ), was not associated with the presence of hemoglobin in CVL. The crude and adjusted association of presence and absence of CVL hemoglobin was evaluated by urinary schistosomiasis status. There was no evidence that active *S haematobium* infection, as diagnosed by either positive urine microscopy for *S haematobium* eggs or detectable CAA, was associated with the presence of hemoglobin in CVL.

## DISCUSSION

Urinary reagent strips are rapid, user-friendly diagnostics used to detect hematuria, an indirect marker of *S haematobium*-related morbidity [11, 26, 27]. Because cervical tissue in women with genital schistosomiasis may be more vascularized than that of women without genital schistosomiasis [6], we evaluated whether identifying hemoglobin in CVL fluid might be associated with either FGS or *Schistosoma* infection status. Regardless of the FGS definition (whether PCR-FGS or visual-FGS) or the method of *Schistosoma* infection diagnosis (whether by CAA or urine microscopy), we found that neither FGS status nor *Schistosoma* infection were associated with CVL hemoglobin detection.

As described by King et al [11], in *S haematobium*-endemic areas, urine reagent strips are frequently used as a predictor of egg-patent *S haematobium* infection, or to provide an estimate of probable *S haematobium* infection. Compared with urine microscopy, urine reagent strips require less equipment and are easier to perform, while still being relatively inexpensive [11, 28]. However, in the community diagnosis of schistosomiasis, the use of urinary reagent strips is challenging in women of reproductive age because hemoglobin can be detected in urine due to other reasons, such as pregnancy, menstruation, and sexually transmitted infection [26]. For example, a Tanzanian study estimated *S haematobium*-related hematuria in women of reproductive age (aged 15–50) compared with urine microscopy as a reference standard. In 3 study areas with *S haematobium* prevalence of 3%, 5%, and 53% the authors of the Tanzanian study report that hematuria, detected by urinary reagent strip, was present in 18%–38% of women not excreting *S haematobium* eggs [26]. In addition, only 54% of hematuria could be attributed to *S haematobium*, and 10%–17% of women without *S haematobium* egg excretion



**Figure 1.** Flowsheet of the study participants ( $n=209$ ). CAA, circulating anodic antigen; CVL, cervicovaginal lavage; FGS, female genital schistosomiasis; HPTN, HIV Prevention Trial Network; PC, population cohort; PCR, polymerase chain reaction; STI, sexually transmitted infection.

had hematuria detected in the intermenstrual period [26]. Although urine microscopy is an imperfect reference standard and has limited sensitivity in low-prevalence areas [29], the Tanzanian study nevertheless illustrates challenges with specificity when using urinary reagent strips in women of reproductive age [26]. Furthermore, the presence of hemoglobin in CVL may be common in women of reproductive age. For example, a Tanzanian cohort of reproductive-age women found that 67% of participants had some degree of CVL hemoglobin detection [18]. The BILHIV study participants self-reported their pregnancy and menstruation status, so it is possible that undetected pregnancy or residual menstrual blood may have influenced the presence of hemoglobin in CVL. Because STIs cause cervicitis, it is not surprising that CVL hemoglobin was detected in a higher proportion of women with STIs in this study compared to women without STIs. Because FGS has not been routinely associated with STIs, adjustment for STIs is not presented in this analysis. However, inclusion of STIs in the model did not significantly change the presented findings (data not shown). The presence and absence of STIs will need to be considered if the detection of CVL hemoglobin is to be taken forward in future work with FGS. In addition, because there are limited data on the performance of reagent strip testing for detecting hemoglobin on fresh versus frozen CVL, in future work, researchers may wish to consider performing reagent strip testing on CVL at the point-of-care.

Participant age, sex, infection intensity [30], and *S haematobium* prevalence [29] may affect urine reagent strip test performance. Before sample selection for this study, the overall prevalence of *Schistosoma* infection in the BILHIV study was 5.5% by urine

microscopy, thus meeting World Health Organization classification of a low-risk community [31]. Because ours is the first study evaluating the association between the presence of CVL hemoglobin and FGS, it is unclear how *S haematobium* and FGS burden may affect reagent strip test performance when used in CVL. Further research will be needed to investigate the association between CVL hemoglobin and FGS in a setting with a higher *S haematobium* prevalence and FGS burden.

Using urine reagent strips to detect CVL hemoglobin in the setting of FGS has not been previously described. Although this approach is novel, this study has some limitations. Although CVL is often performed in research settings, there are limitations to the routine use of CVL for FGS diagnosis. Cervicovaginal lavage is a relatively invasive procedure requiring trained medical staff, a suitable clinical setting, and vaginal speculum insertion. The BILHIV study was cross-sectional, limiting the evaluation of multiple time-points or the long-term impact of different FGS definitions [9]. In addition, the *S haematobium* prevalence was relatively low, and thus the numbers of FGS cases were small, limiting precision in the effect sizes. Thus, we cannot conclusively exclude an association between FGS and the detection of CVL hemoglobin. The BILHIV study participants self-reported their pregnancy and menstruation status, so it is possible that undetected pregnancy or residual menstrual blood may have influenced the presence of hemoglobin in CVL. In addition, because cervical cancer and/or precancerous lesions are among the causes of cervical bleeding [32], it is a limitation that we did not have information on HPV infection prevalence in this cohort. Visual inspection with acetic acid data were not obtained within the BILHIV study, thus

**Table 2. Characteristics of the Study Population (n = 209) and Crude Associations With CVL Hemoglobin Status**

Participant Characteristics	...	CVL Hemoglobin Negative (n)% (n = 71)	CVL Hemoglobin Positive (n)% (n = 138)	P Value <sup>a</sup>
Age in years, median (IQR)	...	23 (22–26)	23 (21–25)	.9 <sup>b</sup>
Marital Status	Single	31 (35.2)	57 (64.8)	.3 <sup>c</sup>
	Married or cohabitating	38 (33.0)	77 (67.0)	...
	Divorced or separated	2 (33.3)	4 (66.7)	...
Education (Highest Level)	None or any primary school	20 (37.0)	34 (63.0)	.8 <sup>c</sup>
	Any secondary school	48 (33.6)	95 (66.4)	...
	Trade, degree or higher	3 (25.0)	9 (75.0)	...
District	Community A	32 (30.5)	73 (69.5)	.3
	Community B	39 (37.5)	65 (62.5)	...
Household Members	1–3	22 (33.9)	43 (66.2)	.7
	4–5	30 (37.0)	51 (63.0)	...
	6+	19 (30.2)	44 (69.8)	...
Employment Status	Not working	50 (32.7)	103 (67.3)	.5
	Working	21 (37.5)	35 (62.5)	...
Reproductive Health Characteristics	...	...	...	...
Age at Sexual Debut (Years)	8–16	36 (40.0)	54 (60.0)	.2
	17–19	29 (30.2)	67 (69.8)	...
	20–24	6 (26.1)	17 (73.9)	...
Lifetime Sexual Partners	1	21 (30.0)	49 (70.0)	.4
	2	14 (28.0)	36 (72.0)	...
	3	14 (40.0)	21 (60.0)	...
	4+	22 (40.7)	32 (59.3)	...
Prior Pregnancy <sup>d</sup>	No	14 (46.7)	16 (53.3)	.2
	Yes	57 (32.0)	121 (68.0)	...
Currently Sexually Active <sup>d,e</sup>	No	11 (35.5)	20 (64.5)	.9
	Yes	60 (33.9)	117 (66.1)	...
Condom Use With Last Sex <sup>f</sup>	No	49 (31.6)	106 (68.4)	.2
	Yes	21 (41.2)	30 (58.8)	...
HIV-1 STATUs	Not detected	55 (31.8)	118 (68.2)	.2
	Detected	16 (44.4)	20 (55.6)	...
Any STIs	Not detected	53 (39.0)	83 (61.0)	.04
	Detected	18 (24.7)	55 (75.3)	...
VIA Status <sup>g</sup>	Acetowhite changes not detected	25 (28.4)	63 (71.6)	.2
	Acetowhite changes detected	4 (50.0)	4 (50.0)	...
Contraceptive Use	...	...	...	...
Condoms	No	57 (32.6)	118 (67.4)	.3
	Yes	14 (41.2)	20 (58.8)	...
Oral contraceptive pill	No	68 (34.9)	127 (65.1)	.4 <sup>c</sup>
	Yes	3 (21.4)	11 (78.6)	...
Injectable	No	41 (38.0)	67 (62.0)	.2
	Yes	30 (29.7)	71 (70.3)	...
Implant	No	63 (33.0)	128 (67.0)	.3
	Yes	8 (44.4)	10 (55.6)	...
Any hormonal contraception <sup>h</sup>	No	30 (39.5)	46 (60.5)	.2
	Yes	41 (30.8)	92 (69.2)	...

Abbreviations: CVL, cervicovaginal lavage; HIV, human immunodeficiency virus; IQR, interquartile range; STI, sexually transmitted infection; VIA, visual inspection with acetic acid.

<sup>a</sup> $\chi^2$  P value unless otherwise indicated.<sup>b</sup>Kruskal-Wallis P value (mean age is presented as a column value, all other variables indicate row percentages).<sup>c</sup>Fisher's exact P value.<sup>d</sup>Participants who responded with "no answer" (n = 1) are not shown in the table.<sup>e</sup>Any sexual activity in the last 6 months.<sup>f</sup>Participants who responded with "no answer" (n = 3) are not shown in the table.<sup>g</sup>VIA results were available for n = 96 participants.<sup>h</sup>Any hormonal contraception is defined as use of injectable agents, implants, or oral contraceptive pills.

**Table 3. Crude and Adjusted Associations of the Presence and Absence of CVL Hemoglobin by FGS and *Schistosoma* Infection Status in the Study Population ( $n = 209$ ), Adjusted for Age, Education, and District of Residence**

Participant Characteristics	...	CVL Hemoglobin Negative (n)% (n = 71)	CVL Hemoglobin Positive (n)% (n = 138)	Crude OR	P Value <sup>a</sup>	Adjusted OR	P Value
<b>FGS and <i>Schistosoma</i> Status</b>							
Cervical Swab PCR	DNA not detected	65 (34.0)	126 (66.0)	Reference	1.0	Reference	.9
	DNA detected	6 (33.3)	12 (66.7)	1.03 (0.37–2.87)	...	0.95 (0.33–2.70)	...
Vaginal swab PCR	DNA not detected	68 (34.9)	127 (65.1)	Reference	.4 <sup>b</sup>	Reference	.3
	DNA detected	3 (21.4)	11 (78.6)	1.96 (0.53–7.28)	...	1.92 (0.51–7.19)	...
Cervicovaginal lavage PCR	DNA not detected	69 (35.4)	126 (64.6)	Reference	.2 <sup>b</sup>	Reference	.1
	DNA detected	2 (14.3)	12 (85.7)	3.29 (0.71–15.10)	...	3.11 (0.67–14.52)	...
Visual FGS <sup>c</sup>	Lesion not detected	60 (34.9)	112 (65.1)	Reference	.3	Reference	.4
	Lesion detected	10 (27.8)	26 (72.2)	1.39 (0.63–3.08)	...	1.44 (0.61–3.43)	...
FGS category	Negative FGS	57 (36.3)	100 (63.7)	Reference	.5	Reference	.4
	Probable FGS	6 (25.0)	18 (75.0)	1.71 (0.64–4.55)	...	1.96 (0.68–5.63)	...
	FGS	8 (28.6)	20 (71.4)	1.43 (0.59–3.44)	...	1.35 (0.54–3.36)	...
PCR FGS (2-3 positive specimens)	0–1 PCR detected	57 (36.3)	100 (63.7)	Reference	.2	Reference	.2
	2–3 PCR detected	3 (20.0)	12 (80.0)	2.28 (0.62–8.42)	...	2.31 (0.62–8.64)	...
PCR FGS (Ct <35)	PCR Ct >35	57 (36.3)	100 (63.7)	Reference	.5	Reference	.4
	PCR Ct <35	4 (26.7)	11 (73.3)	1.57 (0.48–5.15)	...	1.61 (0.48–5.42)	...
Urine microscopy	Not detected	63 (34.2)	121 (65.8)	Reference	.5	Reference	.9
	Detected	8 (32.0)	17 (68.0)	1.11 (0.45–2.70)	...	1.04 (0.41–2.60)	...
Urine CAA	Not detected	60 (35.9)	107 (64.1)	Reference	.2	Reference	.2
	Detected	11 (26.2)	31 (73.8)	1.58 (0.74–3.37)	...	1.64 (0.73–3.67)	...

Abbreviations: CAA, circulating anodic antigen; Ct, cycle threshold; CVL, cervicovaginal lavage; DNA, deoxyribonucleic acid; FGS, female genital schistosomiasis; IQR, interquartile range; OR, odds ratio; PCR, polymerase chain reaction; STI, sexually transmitted infection.

<sup>a</sup> $\chi^2$  P value unless otherwise indicated.

<sup>b</sup>Fisher's exact P value.


<sup>c</sup>Participants ( $n = 1$ ) with images that could not be evaluated are not shown in the table.

data on this variable are incomplete [16]. Given these factors, we cannot exclude residual or unmeasured confounding. We did not evaluate genital specimens for prostate-specific antigen to evaluate the presence of recent sexual contact. Thus, we cannot exclude that cervicovaginal qPCR detected *S haematobium* DNA in eggs present in the semen of a sexual partner [9].

Because the BILHIV study participants self-collected genital swabs, we cannot exclude sampling error nor falsely negative genital swabs. In future studies using self-collected specimens,  $\beta$ -globin PCR could be used as a positive control to confirm the presence of human DNA [9].

## CONCLUSIONS

In conclusion, although urinary reagent strips are a useful diagnostic tool in evaluating the community prevalence of *S haematobium* infection, in our study PCR-FGS, visual-FGS, and active *Schistosoma* infection were not associated with the presence of CVL hemoglobin. This manuscript identifies a knowledge gap regarding the performance of urinary reagent strips as a supplement to CVL in FGS diagnosis, specifically in study populations with a higher FGS burden. However, given the limitations of performing CVL in routine FGS diagnosis, alternate diagnostic strategies are needed. Isothermal DNA amplification methods are field-deployable molecular assays that could be used at the point-of-care to detect *Schistosoma* DNA in self-collected genital swabs [7]. Further research and support are required to make this and other community-based FGS diagnostics available and accessible.



**Figure 2.** Stacked bar chart of presence or absence of hemoglobin (Hb) in cervicovaginal lavage fluid by FGS or *S haematobium* infection status. CAA, circulating anodic antigen; Ct, cycle threshold; FGS, female genital schistosomiasis; PCR, polymerase chain reaction.



## Acknowledgments

We recognize the generous contribution of time and trust from the bilharzia and HIV (BILHIV) study participants, without whom this study would not be possible. We also appreciate the dedication of the BILHIV field team and their enthusiasm for all aspects of field work: Namakau Chola, Ethel Mwansa, Mwiingana Lukonga, Ruth Mwanza, Mervis Kantukaleza, and Judith Lungu. The BILHIV study benefitted greatly from generous and enduring administrative support provided by Mr. Clement Mwakamui (Zambart). We also gratefully acknowledge Pytsje T. Hoekstra (Leiden University Medical Center [LUMC]) and Claudia J. de Dood (LUMC) for performing the circulating anodic antigen analysis as well as Eric A. T. Brienen (LUMC) for performing the female genital schistosomiasis polymerase chain reaction analysis.

**Author contributions.** A. S. S. contributed to conceptualization, data curation, formal analysis, BILHIV project administration, visualization, original manuscript preparation, and manuscript editing and revision. E. L. W. contributed to data curation, formal analysis, supervision, original manuscript preparation, and manuscript editing and revision. L. H. contributed to investigation and manuscript editing and revision. C. R. P. contributed to BILHIV project administration, writing, review, and editing. M. M. contributed to investigation, writing, review, and editing. J. M. contributed to investigation, writing, review, and editing. E. F. K. contributed to investigation, writing, review, and editing. T. M. contributed to investigation, writing, review, and editing. B. L. contributed to resources and manuscript editing and revision. G. J. v. D. contributed to investigation, writing, review, and editing. P. L. A. M. C. contributed to investigation, writing, review, and editing. H. A. contributed to resources, writing, review, and editing. R. J. H. contributed to supervision, resources, writing, review, and editing. L. v. L. contributed to investigation, writing, review, and editing. I. H. contributed to resources, supervision, writing, review, and editing. S. C. F. contributed to supervision, writing, review, and editing. P. C. contributed to resources, investigation, and manuscript editing and revision. A. L. B. contributed to funding acquisition, supervision, original manuscript preparation, and manuscript editing and revision.

**Financial support.** A. L. B. received funding from the Wellcome Trust (Award 205954/Z/17/Z). P. C. received funding from the Research Foundation—Flanders (BOFSTG2019010101) and was financially supported by a Bill & Melinda Gates Foundation Project (OPP1120972). E. L. W. and R. J. H. received funding from MRC Grant Reference MR/R010161/1, and S. C. F. received salary from MRC Grant Reference MR/N023692/1. These awards are jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and are also part of the EDCTP2 program supported by the European Union. HPTN 071 (PopART) was supported by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements UM1-AI068619, UM1-AI068617, and UM1-AI068613, with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); the International Initiative for Impact Evaluation with support from the Bill & Melinda Gates Foundation; the NIAID, the National Institute on Drug Abuse, and the National Institute of Mental Health, all part of the National Institutes of Health. E. F. K. was supported by South-Eastern Regional Health Authority, Norway Project Number 2016055 and the European Research Council under the European Union's Horizon 2020/ERC Grant agreement no. 101057853 (DUALSAVE-FGS).

**Potential conflicts of interest.** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

## References

- Lai YS, Biedermann P, Ekpo UF, et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. *Lancet Infect Dis* 2015; 15:927–40.
- Bustinduy AL, Randriansolo B, Sturt AS, et al. An update on female and male genital schistosomiasis and a call to integrate efforts to escalate diagnosis, treatment

- and awareness in endemic and non-endemic settings: the time is now. *Adv Parasitol* 2022; 115:1–44.
- Kjetland EF, Ndhlovu PD, Mduluzi T, et al. Simple clinical manifestations of genital Schistosoma haematobium infection in rural Zimbabwean women. *Am J Trop Med Hyg* 2005; 72:311–9.
- Swai B, Poggensee G, Mtweve S, Krantz I. Female genital schistosomiasis as an evidence of a neglected cause for reproductive ill-health: a retrospective histopathological study from Tanzania. *BMC Infect Dis* 2006; 6:134.
- Wright ED, Chipangwi J, Hutt MS. Schistosomiasis of the female genital tract. A histopathological study of 176 cases from Malawi. *Trans R Soc Trop Med Hyg* 1982; 76:822–9.
- Jourdan PM, Roald B, Poggensee G, Gundersen SG, Kjetland EF. Increased vascularity in cervicovaginal mucosa with Schistosoma haematobium infection. *PLoS Negl Trop Dis* 2011; 5:e1170.
- Archer J, Patwary FK, Sturt AS, et al. Validation of the isothermal Schistosoma haematobium Recombinase Polymerase Amplification (RPA) assay, coupled with simplified sample preparation, for diagnosing female genital schistosomiasis using cervicovaginal lavage and vaginal self-swab samples. *PLoS Negl Trop Dis* 2022; 16:e0110276.
- Kjetland EF, Hove RJ, Gomo E, et al. Schistosomiasis PCR in vaginal lavage as an indicator of genital Schistosoma haematobium infection in rural Zimbabwean women. *Am J Trop Med Hyg* 2009; 81:1050–5.
- Sturt AS, Webb EL, Phiri CR, et al. Genital self-sampling compared with cervicovaginal lavage for the diagnosis of female genital schistosomiasis in Zambian women: the BILHIV study. *PLoS Negl Trop Dis* 2020; 14:e0008337.
- Land KJ, Boeras DI, Chen XS, Ramsay AR, Peeling RW. Reassured diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. *Nat Microbiol* 2019; 4:46–54.
- King CH, Bertsch D. Meta-analysis of urine heme dipstick diagnosis of Schistosoma haematobium infection, including low-prevalence and previously-treated populations. *PLoS Negl Trop Dis* 2013; 7:e2431.
- Krauth SJ, Greter H, Stete K, et al. All that is blood is not schistosomiasis: experiences with reagent strip testing for urogenital schistosomiasis with special consideration to very-low prevalence settings. *Parasit Vectors* 2015; 8:584.
- Hayes RJ, Donnell D, Floyd S, et al. Effect of universal testing and treatment on HIV incidence—HPTN 071 (PopART). *N Engl J Med* 2019; 381:207–18.
- World Health Organization. Female genital schistosomiasis: a pocket atlas for clinical health-care professionals. Available at: <http://www.who.int/iris/handle/10665/180863>. Accessed 30 April 2021.
- Zambian Ministry of Health. Guidelines for the etiological and clinical management of sexually transmitted infections in Zambia. Lusaka, Zambia: Zambian Ministry of Health; 2017.
- Rafferty H, Sturt AS, Phiri CR, et al. Association between cervical dysplasia and female genital schistosomiasis diagnosed by genital PCR in Zambian women. *BMC Infect Dis* 2021; 21:691.
- Sankaranarayanan R, Wesley R, Thara S, et al. Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's Iodine (VILI) in cervical cancer screening in Kerala, India. *Int J Cancer* 2003; 106:404–8.
- Francis SC, Hou Y, Baisley K, et al. Immune activation in the female genital tract: expression profiles of soluble proteins in women at high risk for HIV infection. *PLoS One* 2016; 11:e0143109.
- Sturt AS, Webb EL, Patterson C, et al. Cervicovaginal immune activation in Zambian women with female genital schistosomiasis. *Front Immunol* 2021; 12:620657.
- Corstjens PL, De Dood CJ, Kornelis D, et al. Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phosphor labels. *Parasitology* 2014; 141:1841–55.
- Corstjens P, de Dood CJ, Knopp S, et al. Circulating anodic antigen (CAA): a highly sensitive diagnostic biomarker to detect active Schistosoma infections—improvement and use during SCORE. *Am J Trop Med Hyg* 2020; 103:50–7.
- Obeng BB, Aryeetey YA, de Dood CJ, et al. Application of a circulating-cathodic-antigen (CCA) strip test and real-time PCR, in comparison with microscopy, for the detection of Schistosoma haematobium in urine samples from Ghana. *Ann Trop Med Parasitol* 2008; 102:625–33.
- Pillay P, Taylor M, Zulu SG, et al. Real-time polymerase chain reaction for detection of Schistosoma DNA in small-volume urine samples reflects focal distribution of urogenital Schistosomiasis in primary school girls in KwaZulu Natal, South Africa. *Am J Trop Med Hyg* 2014; 90:546–52.
- Sturt AS, Webb EL, Himschoot L, et al. Association of female genital Schistosomiasis with the cervicovaginal microbiota and sexually transmitted infections in Zambian women. *Open Forum Infect Dis* 2021; 8:ofab438.
- Sturt AS, Webb EL, Phiri CR, et al. Female genital Schistosomiasis and HIV-1 incidence in Zambian women: a retrospective cohort study. *Open Forum Infect Dis* 2021; 8:ofab349.

26. Poggensee G, Krantz I, Kiwelu I, Feldmeier H. Screening of Tanzanian women of childbearing age for urinary schistosomiasis: validity of urine reagent strip readings and self-reported symptoms. *Bull World Health Organ* **2000**; 78:542–8.
27. Ochodo EA, Gopalakrishna G, Spek B, et al. Circulating antigen tests and urine reagent strips for diagnosis of active schistosomiasis in endemic areas. *Cochrane Database Syst Rev* **2015**; 2015:CD009579.
28. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. *Clin Microbiol Infect* **2015**; 21:529–42.
29. Knopp S, Corstjens PL, Koukounari A, et al. Sensitivity and specificity of a urine circulating anodic antigen test for the diagnosis of *Schistosoma haematobium* in low endemic settings. *PLoS Negl Trop Dis* **2015**; 9:e0003752.
30. Grolimund CM, Barenbold O, Hatz CF, et al. Infection intensity-dependent accuracy of reagent strip for the diagnosis of *Schistosoma haematobium* and estimation of treatment prevalence thresholds. *PLoS Negl Trop Dis* **2022**; 16:e0010332.
31. World Health Organization. Preventive chemotherapy in human helminthiasis: coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers. Available at: [https://apps.who.int/iris/bitstream/handle/10665/43545/9241547103\\_eng.pdf;jsessionid=564247BFB A426C9B5D72B1048671034E?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/43545/9241547103_eng.pdf;jsessionid=564247BFB A426C9B5D72B1048671034E?sequence=1). Accessed 9 June 2022.
32. Mutakha GS, Mwaliko E, Kirwa P. Clinical bleeding patterns and management techniques of abnormal uterine bleeding at a teaching and referral hospital in Western Kenya. *PLoS One* **2020**; 15:e0243166.

## CONFIDENCE IN DOVATO ACROSS TREATMENT SETTINGS<sup>4-9</sup>

Treatment-naïve resistance rates, with up to **3 years of evidence<sup>5-7</sup>**

**0%**  
(n=0/1,885)<sup>\*4</sup>  
REAL-WORLD EVIDENCE

**0.1%**  
(n=1/953)<sup>\*\*1,3,5,5-7</sup>  
RANDOMISED CONTROLLED TRIALS

Treatment-experienced resistance rates, with up to **5 years of evidence<sup>1-3</sup>**

**0.03%**  
(n=10/35,888)<sup>\*4</sup>  
REAL-WORLD EVIDENCE

**0%**  
(n=0/615)<sup>†1,5,8,9</sup>  
RANDOMISED CONTROLLED TRIALS

## >300,000 PEOPLE LIVING WITH HIV HAVE BEEN TREATED WITH DOVATO GLOBALLY<sup>10</sup>

DOVATO is supported by a wealth of evidence, with the outcomes of **>40,000** people living with HIV captured within clinical trials and real-world evidence, including those with:<sup>4-9,11,12</sup>



**NO PRIOR TREATMENT EXPERIENCE<sup>13</sup>**



**NO BASELINE RESISTANCE TESTING<sup>13</sup>**




**HIGH BASELINE VIRAL LOAD**  
(>100,000 copies/mL and even >1M copies/mL)<sup>6,13</sup>



**LOW CD4 + COUNT**  
(≤200 cells/mm<sup>3</sup>)<sup>13</sup>

■ Patients from phase III RCTs

■ Patients from unique real-world cohorts



## IS IT TIME TO RECONSIDER THE VALUE OF THE 2<sup>ND</sup> NRTI?

LEARN MORE 

DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.<sup>13</sup>

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221441

### REFERENCES

- Maggiolo F et al. BMC Infect Dis 2022; 22(1): 782.
- Taramasso L et al. AIDS Patient Care STDS 2021; 35(9): 342-353.
- Ciccullo A et al. JAIDS 2021; 88(3): 234-237.
- ViiV Healthcare. Data on File. REF-223795. 2024.
- Cahn P et al. AIDS 2022; 36(1): 39-48.
- Rolle C et al. Open Forum Infect Dis 2023; 10(3): ofad101.
- Cordova E et al. Poster presented at 12th IAS Conference on HIV Science. 23-26 July 2023. Brisbane, Australia. TUPEB02.
- De Wit S et al. Slides presented at HIV Glasgow. 23-26 October 2022. Virtual and Glasgow, UK. M041.
- Llibre J et al. Clin Infect Dis 2023; 76(4): 720-729.
- ViiV Healthcare. Data on File. REF-220949. 2024.
- Rolle C et al. Poster presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1603.
- Slim J et al. Abstract presented IDWeek. 11-15 October 2023. Virtual and Boston, USA. 1593.
- DOVATO. Summary of Product Characteristics. June 2023.

### PRESCRIBING INFORMATION

[Dovato Prescribing Information](#)

[Legal Notices](#)

[Privacy Policy](#)

[Contact Us](#)

ViiV Healthcare, 980 Great West Road, Brentford, Middlesex, London, UK.

ViiV trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Non-ViiV trademarks are owned by or licensed to their respective owners or licensors.

©2024 ViiV Healthcare group of companies or its licensor. All rights reserved.

Intended for healthcare professionals only.

### ABBREVIATIONS

**3TC**, lamivudine; **CD4**, cluster of differentiation 4; **DTG**, dolutegravir; **FDA**, United States Food and Drug Administration; **FTC**, emtricitabine; **HIV**, human immunodeficiency virus; **ITT-E**, intention-to-treat exposed; **NRTI**, nucleoside/nucleotide reverse transcriptase inhibitor; **RCT**, randomised controlled trial; **RNA**, ribonucleic acid; **TAF**, tenofovir alafenamide fumarate; **TDF**, tenofovir disoproxil fumarate; **XTC**, emtricitabine.

### FOOTNOTES

\*Data extracted from a systematic literature review of DTG+3TC real-world evidence. Overlap between cohorts cannot be fully excluded.

\*\*The reported rate reflects the sum-total of resistance cases calculated from GEMINI I and II (n=1/716, through 144 weeks), STAT (n=0/131, through 52 weeks), and D2ARLING (n=0/106, through 24 weeks).<sup>5-7</sup>

†GEMINI I and II are two identical 148-week, phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority, controlled clinical trials testing the efficacy of DTG/3TC in treatment-naïve patients. Participants with screening HIV-1 RNA ≤500,000 copies/mL were randomised 1:1 to once-daily DTG/3TC (n=716, pooled) or DTG + TDF/FTC (n=717, pooled). The primary endpoint of each GEMINI study was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).<sup>13</sup>

‡STAT is a phase IIIb, open-label, 48-week, single-arm pilot study evaluating the feasibility, efficacy, and safety of DTG/3TC in 131 newly diagnosed HIV-1 infected adults as a first line regimen. The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 24.<sup>6</sup>

§D2ARLING is a randomised, open-label, phase IV study designed to assess the efficacy and safety of DTG/3TC in treatment-naïve people with HIV with no available baseline HIV-1 resistance testing. Participants were randomised in a 1:1 ratio to receive DTG/3TC (n=106) or DTG + TDF/XTC (n=108). The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies/mL at Week 48.<sup>7</sup> Results at week 24 of the study.

|| The reported rate reflects the sum-total of resistance cases calculated from TANGO (n=0/369, through 196 weeks) and SALSA (n=0/246, through 48 weeks).<sup>8,9</sup>

¶TANGO is a randomised, open-label, trial testing the efficacy of DOVATO in virologically suppressed patients. Participants were randomised in a 1:1 ratio to receive DOVATO (n=369) or continue with TAF-containing regimens (n=372) for up to 200 weeks. At Week 148, 298 of those on TAF-based regimens switched to DOVATO. The primary efficacy endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL (virologic non-response) as per the FDA Snapshot category at Week 48 (adjusted for randomisation stratification factor).<sup>8,13</sup>

#SALSA is a phase III, randomised, open-label, non-inferiority clinical trial evaluating the efficacy and safety of switching to DTG/3TC compared with continuing current antiretroviral regimens in virologically suppressed adults with HIV. Eligible participants were randomised 1:1 to switch to once-daily DTG/3TC (n=246) or continue current antiretroviral regimens (n=247). The primary endpoint was the proportion of subjects with plasma HIV-1 RNA ≥50 copies/mL at Week 48 (ITT-E population, snapshot algorithm).<sup>9</sup>